BLUE has been the topic of several other research reports. Morgan Stanley upgraded shares of bluebird bio from an underweight rating to an equal weight rating in a research report on Friday, November 3rd. Evercore ISI upgraded shares of bluebird bio from an in-line rating to an outperform rating and set a $102.00 price target on the stock in a research report on Monday, October 16th. Maxim Group set a $170.00 price target on shares of bluebird bio and gave the stock a buy rating in a research report on Friday, November 17th. CIBC began coverage on shares of bluebird bio in a research report on Thursday, December 21st. They set a market perform rating on the stock. Finally, Goldman Sachs Group reiterated a buy rating and set a $186.00 price target on shares of bluebird bio in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $157.45.
bluebird bio (NASDAQ:BLUE) opened at $170.70 on Tuesday. The stock has a market cap of $8,415.71, a PE ratio of -24.32 and a beta of 2.08. bluebird bio has a 52-week low of $63.90 and a 52-week high of $222.03.
In other news, insider David Davidson sold 6,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $180.30, for a total value of $1,081,800.00. Following the completion of the sale, the insider now directly owns 21,977 shares of the company’s stock, valued at approximately $3,962,453.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Nick Leschly sold 5,435 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the sale, the chief executive officer now directly owns 171,009 shares of the company’s stock, valued at $29,649,540.42. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 222,268 shares of company stock valued at $38,896,707. 3.90% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new stake in bluebird bio during the 3rd quarter worth approximately $2,725,000. Sterling Capital Management LLC bought a new stake in bluebird bio during the 3rd quarter worth approximately $351,000. California Public Employees Retirement System increased its stake in bluebird bio by 1.5% during the 3rd quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock worth $11,826,000 after purchasing an additional 1,300 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares in the last quarter. Finally, Crestline Management LP increased its stake in bluebird bio by 27.7% during the 3rd quarter. Crestline Management LP now owns 12,594 shares of the biotechnology company’s stock worth $1,730,000 after purchasing an additional 2,735 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/13/bluebird-bios-blue-hold-rating-reaffirmed-at-oppenheimer.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.